ADVI Analysis: MACPAC March 2024 Meeting

Pharmaceuticals and Biotech Federal And State Policy

March 11, 2024

MACPAC held a meeting March 7-8 (link). The following relevant topics were discussed: 

  • Proposed Recommendation for Improving the Transparency of Medicaid Financing  
  • Optimizing State Medicaid Agency Contracts: Policy Options   
  • Themes from Expert Roundtable on Physician-administered Drugs 
  • Medicare Savings Programs: Enrollment Trends 

ADVI Angle

Key takeaways from the March meeting include:

  • Proposed Recommendation for Improving the Transparency of Medicaid Financing  
    • Commissioners were generally supportive of the proposed recommendations for increasing transparency of Medicaid financing methods, state-level financing amounts, and provider-level financing amounts. Discussion was focused on asking clarifying questions.  
  • Optimizing State Medicaid Agency Contracts: Policy Options   
    • While commissioners recognized the benefits of each proposed recommendation, many noted that the practicality of implementation may be more difficult due to differing state infrastructures and initiatives. Some commissioners requested to clarify language in the second policy recommendation. 
  • Themes from Expert Roundtable on Physician-administered Drugs
    • Commissioners were interested in relevant stakeholder’s indications towards interest in policies relating to expensive therapies, specifically with interest in CMMI’s CGT Access Model. Other interest was expressed in Value-Based (or outcomes-based) Arrangements, particularly with general interest among stakeholders’ perspectives on these contracts. 
  • Medicare Savings Programs: Enrollment Trends
    • Based on the study conducted with data from 2010-2021, Medicare Savings Programs are growing in enrollment at a steady 3% annual rate. Commissioners were interested in end-of-year enrollment trends and urban/rural enrollment disparities. 

This is an abridged and delayed release. Full ADVI Analysis content is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.


CEO insights

Real analysis from people who’ve been there

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption  

Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …

Marc Samuels, JD, MPH
December 30, 2025

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Inflation Reduction Act Pharmaceuticals and Biotech

Why is Medicare Data Central to IRA Negotiations?

The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …

September 10, 2025

Rare Disease

The Unintended Consequences of Drug Pricing Policies on Orphan Drug Development

Rare diseases impact nearly 1 in 10 people in the US and are largely untreated, with 95 percent lacking FDA-approved …

June 23, 2025

State Policy

ADVI Analysis: HRSA 340B Covered Entity Audits

Analysis of HRSA 340B Covered Entity Audits Since the 340B Drug Pricing Program began in 1992, covered entities’ participation has …

March 10, 2025

ADVI Angle Vertical

Rare Disease State Policy

Prescription Drug Affordability Boards: Access Concerns and Implications for Rare Diseases and Conditions

In recent years, states have increasingly enacted Prescription Drug Affordability Boards (PDABs). While their stated purpose is to increase affordability, …

February 28, 2025

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.